Suchen
Ocugen Inc
OCGNZur Watchlist hinzufügen
1.050USD
+0.030+2.94%
Trading geöffnet 09/14, 12:29（ET）
356.00MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Ocugen Inc Unternehmen
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Ocugen Inc Profil
BörsenkürzelOCGN
Name des UnternehmensOcugen Inc
IPO-datumDec 03, 2014
CEOMusunuri (Shankar)
Anzahl der mitarbeiter95
WertpapierartOrdinary Share
GeschäftsjahresendeDec 03
Addresse11 Great Valley Parkway
StadtMALVERN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl19355
Telefon14843284701
Websitehttps://ocugen.com/
BörsenkürzelOCGN
IPO-datumDec 03, 2014
CEOMusunuri (Shankar)
Führungskräfte von Ocugen Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.36M
--
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.36M
--
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
214.50K
--
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
214.50K
--
Mr. Ramesh Ramachandran, CPA
Mr. Ramesh Ramachandran, CPA
Chief Accounting Officer
Chief Accounting Officer
1.80K
--
Dr. Shankar Musunuri, Ph.D.
Dr. Shankar Musunuri, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Uday B. Kompella, Ph.D.
Dr. Uday B. Kompella, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kirsten Castillo
Ms. Kirsten Castillo
Independent Director
Independent Director
--
--
Ms. Rita Johnson-Greene
Ms. Rita Johnson-Greene
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
--
--
Mr. Mohamed Genead, M.D.
Mr. Mohamed Genead, M.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.36M
--
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.36M
--
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
214.50K
--
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
214.50K
--
Mr. Ramesh Ramachandran, CPA
Mr. Ramesh Ramachandran, CPA
Chief Accounting Officer
Chief Accounting Officer
1.80K
--
Dr. Shankar Musunuri, Ph.D.
Dr. Shankar Musunuri, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Ocugen Inc?
Die fünf größten Anteilseigner von Ocugen Inc sind: Mr. Junge Zhang, Ph.D.
Wie viele Institutionen halten Anteile an Ocugen Inc (OCGN)?
Mit Stand vom 2026Q1 halten 276 Institutionen Anteile an Ocugen Inc, mit einem Gesamtmarktwert von etwa 81.01M, was 24.06% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 20937.00 gestiegen.